MedTrace Logo

Encouraging Flu Vaccination Among High-Risk Patients Identified by ML

NCT04323137 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 117649

Last updated 2024-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of the current study is to test different interventions to determine the most effective way to promote flu vaccine uptake in a high-risk population identified by an "artificial intelligence" (AI) or machine learning (ML) algorithm. The specific aims are:

1. Evaluate the effect on flu vaccination rates of informing health-system patients who are identified by an ML analysis of EHR data to be at high risk for flu complications that they are at high risk with either (a) no additional explanation, (b) an explanation that this determination comes from an analysis of their medical records, and (c) the additional explanation that an AI or ML algorithm made this determination.
2. Evaluate the effects of the same three interventions on diagnoses of flu in the same patients.

Conditions

  • Influenza
  • Vaccination
  • Health Promotion
  • Health Behavior
  • Risk Reduction

Interventions

BEHAVIORAL

Risk reduction

Mailed letter, SMS, and/or patient portal message

BEHAVIORAL

Medical records-based recommendation

Mailed letter, SMS, and/or patient portal message

BEHAVIORAL

Algorithm-based recommendation

Mailed letter, SMS, and/or patient portal message

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Geisinger Clinic

    lead OTHER

Principal Investigators

  • Christopher Chabris, PhD · Geisinger Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-05-31
Completion
2021-09-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04323137 on ClinicalTrials.gov